Abstract
Cancer cachexia is a highly debilitating paraneoplastic disease observed in more than 50% of patients with advanced cancers and directly contributes to 20% of cancer deaths. Loss of skeletal muscle is a defining characteristic of patients with cancer cachexia and is associated with poor survival. The present study reveals the involvement of a myogenic transcription factor Myocyte Enhancer Factor (MEF) 2C in cancer-induced skeletal muscle wasting. Increased skeletal muscle mRNA expression of Suppressor of Cytokine Signaling (Socs) 3 and the IL-6 receptor indicative of active IL-6 signaling was seen in skeletal muscle of mice bearing the Colon 26 (C26) carcinoma. Loss of skeletal muscle structural integrity and distorted mitochondria were also observed using electron microscopy. Gene and protein expression of MEF2C was significantly downregulated in skeletal muscle from C26-bearing mice. MEF2C gene targets myozenin and myoglobin as well as myokinase were also altered during cachexia, suggesting dysregulated oxygen transport capacity and ATP regeneration in addition to distorted structural integrity. In addition, reduced expression of calcineurin was observed which suggested a potential pathway of MEF2C dysregulation. Together, these effects may limit sarcomeric contractile ability and also predispose skeletal muscle to structural instability; associated with muscle wasting and fatigue in cachexia.
Highlights
Cachexia is a hypermetabolic wasting syndrome involving the progressive depletion of adipose tissue and skeletal muscle mass, irrespective of nutritional intake
In this study we demonstrate a novel association between dysregulated MEF2C gene expression and prominent ultrastructural changes in muscle structural integrity and mitochondria in cancer cachexia
The weight loss was associated with myofiber atrophy with a more prominent change in type 2 myofiber cross-sectional area and agreed with previous study which showed the change in diameter ([30]; Figure 1)
Summary
Cachexia is a hypermetabolic wasting syndrome involving the progressive depletion of adipose tissue and skeletal muscle mass, irrespective of nutritional intake. It has the highest incidence in patients with gastrointestinal and pancreatic cancers (83-87%) [1]. Cachexia is associated with severe weight loss, muscle wasting, weakness and fatigue and causes psychosocial distress and dependency upon others; significantly impairing quality of life [2]. Reversal of weight loss has been shown to be associated with increased longevity in tumor-bearing (TB) mice [3]. A better understanding of the molecular process underlying skeletal muscle wasting due to cancer cachexia is critical in designing intervention strategies; beneficing both the quality and longevity of cachectic patients
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
